QPPV.COM KNOWLEDGE ASSESSMENT

Ustekinumab: Classification, Mechanism, Clinical Use and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Ustekinumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which benefit should be explicitly included in periodic benefit-risk evaluation for ustekinumab in inflammatory bowel disease?

Only improvement in laboratory values unrelated to disease control Reduction in corticosteroid exposure, hospitalisation avoidance and maintenance of remission Only the number of product presentations available Absence of any reported injection-site reaction

Question 2 of 10 Which molecular feature best explains why ustekinumab can affect both IL-12 and IL-23 signalling?

It binds the p19 subunit unique to IL-23 It binds the p40 subunit shared by IL-12 and IL-23 It blocks IL-12Rbeta1 by depleting receptor-bearing cells It neutralises all cytokines produced by activated T cells

Question 3 of 10 Which treatment sequence is most characteristic of ustekinumab use in Crohn disease or ulcerative colitis?

Subcutaneous induction followed by intravenous maintenance Oral induction followed by subcutaneous maintenance Intravenous induction followed by subcutaneous maintenance Intramuscular induction followed by oral maintenance

Question 4 of 10 Which additional information is most useful when assessing a serious infection reported in a patient with inflammatory bowel disease?

The patient's preferred injection device colour The infection site and organism, disease activity and concomitant corticosteroid use Only the date of the first ustekinumab prescription The presence of anti-drug antibodies regardless of clinical context

Question 5 of 10 Which tuberculosis information has the greatest value for interpreting a tuberculosis-related report?

Only whether the patient had previously received a subcutaneous injection Baseline screening, distinction between latent and active disease, prophylaxis and microbiological or imaging evidence Only the patient's total number of ustekinumab doses Whether the patient had a history of mild injection-site erythema

Question 6 of 10 How should ustekinumab's primary pharmacological action be characterised?

Selective depletion of immune cells expressing IL-12Rbeta1 Broad suppression of antibody production by B cells Ligand neutralisation that prevents IL-12 and IL-23 from engaging their receptor pathway Irreversible inhibition of intracellular cytokine synthesis

Question 7 of 10 Which information most helps distinguish secondary loss of response from primary non-response?

Whether the patient prefers a prefilled syringe Whether the patient initially benefited, together with adherence, dosing interval and objective disease activity The patient's tumour screening history alone The batch number without any treatment-response chronology

Question 8 of 10 Which finding would most strongly support a clinically meaningful assessment of suspected posterior reversible encephalopathy syndrome?

Headache alone without further clinical information A nonspecific report of fatigue after maintenance dosing Compatible neurological symptoms with blood-pressure data and supportive neuroimaging A positive anti-drug antibody test in the absence of neurological symptoms

Question 9 of 10 Which governance principle best summarises mature pharmacovigilance for ustekinumab?

Treat every exposure as identical because the active substance is the same Separate all indications completely and avoid molecule-level assessment Manage ustekinumab as a coherent pharmacological entity while preserving indication, age, route, phase and product granularity Focus exclusively on rare serious events and disregard medication-use issues

Question 10 of 10 A patient develops acute symptoms during the first ustekinumab administration for Crohn disease. Which contextual factor is most important when initially characterising the event?

Whether the event occurred during intravenous induction or later subcutaneous maintenance Whether the patient previously had plaque psoriasis Whether the antibody is fully human IgG1 kappa Whether the patient had ever received a topical corticosteroid

Ustekinumab: Classification, Mechanism, Clinical Use and Pharmacovigilance Assessment

Cookie Settings